HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.

Abstract
Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors. We tested the hypothesis that therapy with valsartan, an angiotensin receptor blocker and amlodipine, an antioxidant calcium channel blocker will reduce oxidative stress and the plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase. We confirmed that compared with age- and gender-matched healthy controls, ESRD patients have excessive oxidative stress and arginine methylation as indexed by elevated plasma levels of oxidation products of lipids (13-hydroxyoctadecadienoic acid (13-HODE)), thiols (oxidized:reduced glutathione, oxidized glutathione (GSSG):GSH), proteins, and nucleic acids, and the methylation products ADMA and symmetric dimethylarginine (SDMA). We undertook a double blind, crossover study of equi-antihypertensive treatment with amlodipine and valsartan for 6 weeks each to test our hypothesis. Both treatments significantly reduced GSSG:GSH, 8-hydroxy 2-deoxyguanosine, ADMA, and SDMA levels and amlodipine reduced 13-HODE. We conclude that hypertensive patients with ESRD receiving HD have evidence of extensive oxidation of lipids, thiols, proteins, and nucleic acids and methylation of arginine that could contribute to CVD. Many of these changes can be reduced by short-term treatment with amlodipine and valsartan.
AuthorsS Aslam, T Santha, A Leone, C Wilcox
JournalKidney international (Kidney Int) Vol. 70 Issue 12 Pg. 2109-15 (Dec 2006) ISSN: 0085-2538 [Print] United States
PMID17063175 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Calcium Channel Blockers
  • Tetrazoles
  • Amlodipine
  • N,N-dimethylarginine
  • Valsartan
  • Arginine
  • Valine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amlodipine (administration & dosage)
  • Angiotensin II Type 1 Receptor Blockers (administration & dosage)
  • Arginine (analogs & derivatives, blood)
  • Blood Pressure (drug effects)
  • Calcium Channel Blockers (administration & dosage)
  • Cross-Over Studies
  • Female
  • Humans
  • Hypertension, Renal (drug therapy, metabolism)
  • Kidney Failure, Chronic (drug therapy, metabolism)
  • Male
  • Methylation (drug effects)
  • Middle Aged
  • Oxidative Stress (drug effects)
  • Renal Dialysis
  • Tetrazoles (administration & dosage)
  • Valine (administration & dosage, analogs & derivatives)
  • Valsartan

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: